Simplify Asset Management Inc. Purchases Shares of 290,000 COMPASS Pathways PLC Sponsored ADR $CMPS

Simplify Asset Management Inc. acquired a new position in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 290,000 shares of the company’s stock, valued at approximately $1,662,000. Simplify Asset Management Inc. owned 0.30% of COMPASS Pathways at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Nantahala Capital Management LLC boosted its holdings in COMPASS Pathways by 182.9% during the first quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company’s stock worth $8,092,000 after buying an additional 1,829,232 shares in the last quarter. Woodline Partners LP raised its position in shares of COMPASS Pathways by 279.9% in the first quarter. Woodline Partners LP now owns 1,754,856 shares of the company’s stock worth $5,019,000 after acquiring an additional 1,292,927 shares during the period. Hsbc Holdings PLC acquired a new stake in shares of COMPASS Pathways during the 2nd quarter valued at about $3,011,000. Driehaus Capital Management LLC acquired a new stake in shares of COMPASS Pathways during the 1st quarter valued at about $2,007,000. Finally, Schroder Investment Management Group purchased a new position in shares of COMPASS Pathways in the 2nd quarter valued at about $1,525,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Stock Up 0.7%

NASDAQ CMPS opened at $6.73 on Tuesday. The business has a fifty day moving average price of $5.98 and a 200 day moving average price of $5.12. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. The company has a market cap of $646.21 million, a P/E ratio of -2.47 and a beta of 1.93. COMPASS Pathways PLC Sponsored ADR has a one year low of $2.25 and a one year high of $7.15.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. Research analysts anticipate that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on CMPS. BTIG Research increased their price target on COMPASS Pathways from $7.00 to $14.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of COMPASS Pathways in a report on Wednesday, October 8th. Finally, Morgan Stanley upped their price objective on shares of COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, COMPASS Pathways has a consensus rating of “Moderate Buy” and a consensus target price of $15.88.

COMPASS Pathways Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.